Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing - Wikidata - awgldk - TriplyDB

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

http://www.wikidata.org/entity/Q37364896

about

Glucagon-like peptide analogues for type 2 diabetes mellitus Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives Albumin-based drug delivery: harnessing nature to cure disease Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors Impact of postprandial glycaemia on health and prevention of disease Therapy for obesity based on gastrointestinal hormones The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Once-weekly albiglutide in the management of type 2 diabetes: patient considerations.Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study.An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.The evolving place of incretin-based therapies in type 2 diabetes Decreased gastric motility in type II diabetic patients Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus.Emerging role of GLP-1 receptor agonists in the treatment of obesity.Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.Incretin therapy--present and future.Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes.Incretin agents in type 2 diabetes.Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential.Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes.Incretin-based therapies.Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.

P2860

Q24235918-616A5EDD-26AE-4DB5-B7FA-F06B61622BA3 Q24568148-1525F3BA-12EB-4495-B87E-1B7407D44002 Q26746901-B48C35D0-8AC5-42C3-BD5D-F618974FEA77 Q26765789-4D765DFE-3948-475B-9179-23D7D03A94CE Q26778608-737983F3-AE4F-47CA-8C0D-B291657C9318 Q26862823-4A2BC2F6-FBAF-41D8-9192-A867869FC8E2 Q27006777-F0A9B57A-3856-4369-BA85-09B8704C0FEA Q28257521-D0E054FA-8C60-419B-850C-30DE64AD185C Q28397980-1C831C15-566B-4459-ACCE-C898344F767F Q30249371-EE5086F4-0571-4F86-8790-B55D0851CF8A Q30300201-9109BC65-F0DF-4B53-84F1-3A1F93AFC87C Q30426407-D3352C4B-C40C-45F3-B685-907BB8CF8FDB Q33728226-FD4D1FFC-5E30-43D9-9661-9051C2CBDEE9 Q33767049-FC1F8584-39BD-437F-8CBB-4428CA216FED Q33785146-70959D1D-0AF1-452F-B9EC-113750745A5A Q33786150-4C89C925-642E-4F10-9E26-7D3FFB6D1113 Q33866808-FACF4795-F97E-49F8-A10C-17954D796F31 Q34043578-03BF8D8C-A57C-490D-96CA-0D088351CFB7 Q34180791-E98E367F-5737-4398-9B12-50054DE56B10 Q34620447-C5B7519D-CD5E-4394-A520-99AEE3317B4D Q34620465-C4CC40FF-1D22-43E3-A513-C8330F6FE0B7 Q35640531-929E8BD9-D79C-4089-96D6-0D3D04062887 Q35760283-62CD6026-6606-494C-A22E-F3B374EEACE3 Q35784245-99493BFC-5EE4-477B-8D05-30FD901CA3BE Q36011993-9FF42A8A-D7C9-4134-B4D2-ED4CE09869D7 Q36441684-D3B7E1B1-283A-444A-8494-CCF114204665 Q36520655-117C82EB-F997-4F34-AB08-AC27A3DEF19C Q36629515-EDC3B724-5682-48AE-9A55-6E5FDD0B3672 Q36972891-2C49D6AA-F33E-462F-8117-47DAF9161937 Q37367934-D3D1B564-E264-44AE-A51C-6E12C4BB5A57 Q37402786-F46B60FA-295C-49E4-81F8-ED10F5B94234 Q37410215-BEDACCA8-9253-4D3C-AEC0-B8A3E473F9B9 Q37446672-95681080-FC58-4F39-B214-BCCE27EBB16F Q37635255-FFEBF2DF-818D-4DA9-996C-A97E128DAC5F Q37724230-A73C3460-BDDF-4171-BE24-A4BD8BED8E92 Q37772709-6104C981-AFEC-4BA1-A3FD-5088B2F206D0 Q37852801-53E7A963-4D41-4D8A-9CE6-FA01B5002E09 Q37875220-F8BA5D8C-DA2A-409A-B432-ECEAE906F55A Q37894864-9B4DB496-402F-48E3-A678-F91E74F1E925 Q37897817-E0B6DB3C-8825-46CC-A652-8A133A5ACBF1

P2860

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

http://www.wikidata.org/entity/Q37364896

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Potential of albiglutide, a lo ...... , biweekly, and monthly dosing

@en

Potential of albiglutide, a lo ...... biweekly, and monthly dosing.

@nl

type

label

Potential of albiglutide, a lo ...... , biweekly, and monthly dosing

@en

Potential of albiglutide, a lo ...... biweekly, and monthly dosing.

@nl

prefLabel

Potential of albiglutide, a lo ...... , biweekly, and monthly dosing

@en

Potential of albiglutide, a lo ...... biweekly, and monthly dosing.

@nl

P1433

Q37364896-8EA4DACA-F7B4-4DF6-B6C8-BEA38A5DB682

P1476

Q37364896-B4E6D3BB-0898-4459-AAE6-62B963916BF9

P2093

Q37364896-6C8E3B35-4842-487C-86FC-171B52C77B13

Q37364896-7B7008B9-EE0B-4A99-AE7E-6A5CAB2D193A

Q37364896-988C2A52-A229-4235-919A-8D120BC7BB1C

Q37364896-D92463AE-FBC3-4D75-948C-2A61A9F49A68

Q37364896-DDBF4C20-8497-4400-A393-A54D80DE13FC

P2860

Q37364896-0BE7CE6D-DD85-450E-904F-533007DF5254

Q37364896-11DC4270-8C1E-4159-9417-D45119035AB7

Q37364896-1FF6931C-BBBE-4513-A677-8BD957D6A8E8

Q37364896-28CB436F-C3D9-41E0-80F3-AAEF82E0984D

Q37364896-366E9347-2BA3-4FB4-8DFA-771BBE7865FD

Q37364896-4B08D038-1EC3-4D4F-873F-8DA8BE517C89

Q37364896-4BCE0A83-2082-485E-87E0-C3D9856BAC9B

Q37364896-5406DFDE-028E-4684-A21C-468E5CC86504

Q37364896-5CFAE2B5-D70D-441F-8098-7F6C87E17402

Q37364896-65872401-BF23-4E5F-9AF8-386C282231AD

P304

Q37364896-141E5008-213E-44FB-A3F5-0F06B4FEA1A7

P31

Q37364896-FC00C77E-AD50-4F41-A650-510D3D70C90B

P356

Q37364896-5DC159B5-DFC0-41EB-A4B5-1AA8B01B60C4

P407

Q37364896-73EA02C3-D0F5-4EE4-AF88-B4F9E1ABF282

P433

Q37364896-A7BCF4A8-B587-4245-BCCF-6669C37567E9

P478

Q37364896-D43B427F-FA49-46A3-829D-638A57286681

P50

Q37364896-9CA3C494-E56B-476F-AA88-4B5B819CDF39

P577

Q37364896-81739A59-3873-4B2E-869C-F88FB31D35D8

P5875

Q37364896-4C4A62CE-46C4-45BC-9579-1F428F4E639B

P698

Q37364896-57131335-8262-4EE4-B29C-BCEF5E89BE8A

P921

Q37364896-12ACB3E8-D0DA-405B-9B8F-FA1E42EF5307

P932

Q37364896-813BE2A3-ADFB-4617-BD18-56D6EE486469

P356

P1433

P1476

Potential of albiglutide, a lo ...... , biweekly, and monthly dosing

@en

P2093

Albiglutide Study Group

http://www.w3.org/2001/XMLSchema#string

Fred Yang

http://www.w3.org/2001/XMLSchema#string

Jane Reusch

http://www.w3.org/2001/XMLSchema#string

Mark Bush

http://www.w3.org/2001/XMLSchema#string

Murray Stewart

http://www.w3.org/2001/XMLSchema#string

P2860

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

10-year follow-up of intensive glucose control in type 2 diabetes

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

P304

1880-1886

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC09-0366

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Julio Rosenstock

P577

2009-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26661569

http://www.w3.org/2001/XMLSchema#string

P698

19592625

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2752910

http://www.w3.org/2001/XMLSchema#string